Titre du document / Document title

Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to ventolin

Auteur(s) / Author(s)

STEWART B. A. ⁽¹⁾ ; AHRENS R. C. ⁽²⁾ ; CARRIER S. ⁽³⁾ ; FROSOLONO M. ⁽³⁾ ; LUX C. ⁽²⁾ ; HAN S.-H. ⁽²⁾ ; MILAVETZ G. ⁽⁴⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Healthcare Professional Associates, Amarillo, TX, ETATS-UNIS
⁽²⁾ Allergy/Pulmonary Division, Department of Pediatrics, College of Medicine, The University of Iowa, Iowa City, IA, ETATS-UNIS
⁽³⁾ Baker Norton Pharmaceuticals, Inc, Miami, FL, ETATS-UNIS
⁽⁴⁾ Division of Clinical and Administrative Pharmacy, College of Pharmacy, The University of Iowa, Iowa City, IA, ETATS-UNIS
Norton Healthcare, Ltd, Harlow, ROYAUME-UNI

Résumé / Abstract

Study objective: To use histamine bronchoprovocation and bioassay statistical procedures to evaluate the in vivo bioequivalence of a generic albuterol metered-dose inhaler (MDI). Design: A randomized, double-blind, balanced, crossover design was used to determine the potency of each generic albuterol MDI actuation relative to Ventolin (Glaxo Wellcome; Research Triangle Park, NC) administration. One treatment was administered on each of 4 study days. A histamine bronchoprovocation procedure was initiated 1.25 h before and 15 min after administration of the study treatment. Patients: Twenty-four nonsmoking subjects with mild-to-moderate asthma were studied (18 to 65 years of age; FEV₁, > 60% of predicted; and provocative concentration of histamine causing a 20% fall in FEV₁ [PC₂₀], ≤ 8 mg/mL at screening). Interventions: One and four actuations (90 and 360 μg, respectively) of the generic MDI and of Ventolin MDI. Placebo inhalers were used to maintain blinding of inhaler and doses. Measurements and results: The primary outcome variable was histamine PC₂₀ measured after study treatment administration. A significant dose-effect relationship was present (p < 0.0001). Deviation from parallelism of the generic and Ventolin dose-response curves (p = 0.95) and differences in overall mean response between the two formulations (p = 0.68) were not significant. Using Finney 2 × 2 bioassay statistical procedures, we estimated that one actuation of the generic albuterol MDI was equivalent to 1.01 puffs of Ventolin (90% confidence interval, 0.69 to 1.50). Conclusion: The generic albuterol MDI delivers a quantity of albuterol to the β₂-receptor site in the lung that is the bioequivalent to Ventolin. Further, this study reinforces the validity of this statistical methodology for determining in vivo bioequivalence.

Revue / Journal Title

Chest   ISSN 0012-3692   CODEN CHETBF 

Source / Source

2000, vol. 117, n^o3, pp. 714-721 (23 ref.)

Langue / Language

Anglais

Editeur / Publisher

American College of Chest Physicians, Northbrook, IL, ETATS-UNIS  (1970) (Revue)

Mots-clés anglais / English Keywords

Asthma ; Inhaler ; Bronchodilator ; Bioavailability ; Lung function ; Treatment ; Exploration ; Human ; Respiratory disease ; Obstructive pulmonary disease ; Chemotherapy ;

Mots-clés français / French Keywords

Asthme ; Inhalateur ; Bronchodilatateur ; Biodisponibilité ; Fonction respiratoire ; Traitement ; Exploration ; Homme ; Albuterol ; Ventoline ; Appareil respiratoire pathologie ; Bronchopneumopathie obstructive ; Chimiothérapie ;

Mots-clés espagnols / Spanish Keywords

Asma ; Inhalador ; Broncodilatador ; Biodisponibilidad ; Función respiratoria ; Tratamiento ; Exploración ; Hombre ; Aparato respiratorio patología ; Broncopneumopatía obstructiva ; Quimioterapia ;

Localisation / Location

INIST-CNRS, Cote INIST : 7627, 35400008208010.0190